

---

---

--	--	--	--

---

1

			-	
			-	
			-	
			-	
			-	

ROS dT2d

|--|--|--|--|--|




1 2023 3  
ANDA

2023 3 17

2 2023 3

Oregovomab

Oregovomab

Oregovomab  
2023 3 28

3 2023 3 TechdowUSAInc.

2023 3 30  
ANDA

2023 4 4

4 2023 4

0.4ml

5 16

2023 1 1
















---


